Analyst Rating Update on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) : Zacks Investment Research ranks Bristol-Myers Squibb Company (BMY) as 2, which is a Buy recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. 2 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 17 research analysts is 2.32, which indicates as a Buy.

Bristol-Myers Squibb Company (BMY) : 14 investment research analysts covering Bristol-Myers Squibb Company (BMY) have an average price target of $74.71 for the near short term. The highest target price given by the Brokerage Firm to the stock is $100 and the lowest target is $48 for the short term. Analysts expect the variance to be within $13.79 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Jefferies maintains its outlook on Bristol-Myers Squibb Company (NYSE:BMY). The current rating of the shares is Hold, according to the research report released by the firm. The brokerage firm raises the price target from $77 per share to $80 per share. The rating by the firm was issued on July 14, 2016.


Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $74.93 on Wednesday but the bulls could not build on the opening and the stock topped out at $75.06 for the day. The stock traded down to $74.25 during the day, due to lack of any buying support eventually closed down at $74.80 with a loss of -0.33% for the day. The stock had closed at $75.05 on the previous day. The total traded volume was 4,349,626 shares.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.